Kjetil B.
- Country
- Norway
- Department
- Oncology Department
Research Overview
- (Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
- Long-term Safety Evaluation of Oral Brigimadlin Monotherapy in Patients with Solid Tumors: A Phase II, Single-Arm, Open-Label Rollover Study
- PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma
Data & Insights
Has run more than one trial at 107 of 250 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating gastrointestinal stromal tumors (GIST), with particular focus on advanced and previously treated cases. Their research encompasses various therapeutic approaches for patients who have undergone prior imatinib treatment.
- Advanced GIST Management
- Post-Imatinib Treatment Strategies
- Adjuvant Therapy Optimization
Soft Tissue Sarcomas
Demonstrates expertise in treating various forms of soft tissue sarcomas, including rhabdomyosarcoma, angiosarcoma, and dedifferentiated liposarcoma. Their work extends to both localized and advanced disease states.
- Neoadjuvant Treatment Approaches
- Advanced Sarcoma Management
- Novel Therapeutic Combinations
Rare Tumor Types
Focuses on rare oncological conditions including tenosynovial giant cell tumor and Ewing sarcoma. The investigator's work encompasses both primary and recurrent disease settings.
- Refractory Disease Treatment
- Novel Therapeutic Evaluation
- Treatment Response Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.